Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.

Therapeutic advances in respiratory disease - 1 Jan 2026

Šarc Irena, Morgan Tina, Požek Igor, Kopač Peter

Abstract excerpt

BACKGROUND: Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype is linked to frequent exacerbations and increased oral corticosteroid (OCS) use. Mepolizumab, an anti-IL-5 monoclonal antibody, has shown efficacy in eosinophilic airway disease. This study assessed its real-life effectiveness in COPD patients with frequent OCS-requiring exacerbations. OBJECTIVES: To evaluate the effectiveness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Eosinophils

Share to Follow-Up Studies

Share to Pulmonary Disease, Chronic Obstructive

Share to Time Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41685694
DOI: 10.1177/17534666251414352
PMCID: PMC12905080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.PMID 41685694Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Burden of disease associated with a COPD eosinophilic phenotype.Semantic proximity Read ↗

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

The effect of biologics on lung function improvements among severe eosinophilic asthma patients with partial reversibility or fixed obstructive defects: A retrospective analysisSemantic proximity Read ↗

Mepolizumab for COPD with Eosinophilic Phenotype following HospitalizationSemantic proximity Read ↗

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic PhenotypeSemantic proximity Read ↗

Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.Semantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Chronic obstructive pulmonary disease's eosinophilic phenotype: Clinical characteristics, biomarkers and biotherapy.Semantic proximity Read ↗

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.Semantic proximity Read ↗

Susceptibility to exacerbation in chronic obstructive pulmonary disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.